The FDA granted fast track status to givinostat for treating high-risk polycythemia vera, supporting its potential shown in the ongoing phase 3 GIV-IN PV trial.

During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of ...

T-DXd plus THP led to significant improvements in pathologic complete response in patients with early-stage, HER2+ breast ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

During a live event, Ahmad Tarhini, MD, PhD, discussed the RELATIVITY-047 trial of nivolumab/relatlimab vs nivolumab alone in ...

Transplantation improves survival after cladribine-based therapy for patients with relapsed/refractory acute myeloid leukemia ...

Ruben Olivares, MD, discusses the important implications of the first transcontinental robot-assisted focal therapy procedure for prostate cancer.

The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been ...

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they ...

With the clinical hold on the tab-cel application lifted, phase 2 and 3 trials of the T-cell immunotherapy in patients with ...